Market revenue in 2023 | USD 90.7 million |
Market revenue in 2030 | USD 169.8 million |
Growth rate | 9.4% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Non-cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 87.43% in 2023. Horizon Databook has segmented the Singapore hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in adoption of newborn screening in Singapore in one of the key factors positively impacting growth of hereditary testing market in this country. The significant advancements in training and development of new tests by several public & private entities resulted in improvements in newborn screening.
For instance, Department of Pathology & Laboratory Medicine of KKH Women’s & Children’s Hospital planned to include screening of congenital adrenal hyperplasia and SCID in infants as part of National Expanded Newborn screening program. Increasing awareness of hereditary cancers & screening and genetic counseling sessions for patients at high risk of hereditary cancer have boosted the number of patients seeking screening hereditary cancers from genetics clinics.
Cancer Genetics Service, a clinic started at National Cancer Centre Singapore (NCCS), currently evaluates around 100 to 120 people per year. Similarly, National University Cancer Institute, Singapore (NCIS), diagnoses around 60 to 80 new patients a year for cancer genetic risk evaluation.
Horizon Databook provides a detailed overview of country-level data and insights on the Singapore hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Singapore hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account